EP2615909A1

EP2615909A1 - Method for treating cells with a view to cryogenically freezing same, and method for the cryopreservation of cells implementing such a method

Info

Publication number: EP2615909A1
Application number: EP11773495.4A
Authority: EP
Inventors: Frédéric SALDMANN; Gérard FRIEDLANDER
Original assignee: Immunobank NV
Current assignee: Immunobank NV
Priority date: 2010-09-16
Filing date: 2011-09-13
Publication date: 2013-07-24
Also published as: WO2012035250A1; FR2964981A1

Abstract

The invention relates to a method for treating cells with a view to cryopreserving said cells, characterised in that said method includes the following steps: adding at least one saturated oxygen carrier to said cells prior to freezing and after thawing, said oxygen carrier including human or animal haemoglobin and/or a human or animal haemoglobin substitute; adding a combination of cryoprotectants having high and low molecular weights to said cells, reducing the formation of ice crystals in the extra- and intracellular compartments; and adding at least one gel of plant origin to said cells in order to protect the cells during the freezing and thawing phases, said gel of plant origin including agarose and/or alginate. The invention also relates to a method for the cryopreservation of cells implementing such a treatment method.

Description

"Method of treating cells with a view to their cryogenization and method of cryopreservation of cells implementing such a method"

The present invention relates to a method of treating cells for cryopreservation. It also relates to a cryopreservation method for cells implementing such a method.

The field of the invention is the field of the cryopreservation of human or animal cells for reuse on the same subject or on a different subject.

The process leading to a transplant of organs, tissues or cells involves several more or less complex steps, including a step of conservation lasting more or less long. Deep cold cryopreservation remains the technique of choice for the long-term preservation, for example, of cell viability for several years. Cryopreservation uses substances known as cryoprotectants that protect cells from unwanted effects associated with freezing and thawing.

The main objective of cryopreservation techniques is to obtain, after thawing, the largest number of viable cells. When the initial sample is composed of heterogeneous cell populations, the secondary objective is to preserve the viability of different cell subpopulations and in particular those that are least represented.

An object of the present invention is to propose a method for treating human or animal cells in cryopreservation to improve cryopreservation.

Another object of the invention is to provide a method for treating human or animal cells making it possible to obtain a larger number of living cells after cryogenization compared with the state of the art.

Finally, it is also an object of the present invention to provide a method of treating human or animal cells to better preserve the viability of different cell subpopulations and in particular those which are least represented during a cryopreservation.

The invention achieves at least one of these objects by a method of treating cells for cryopreservation of said cells, characterized in that it comprises the following steps:

adding cells to at least one cell oxygenating substance prior to freezing and after thawing,

addition of cells of a combination of cryoprotectants of high and low molecular weight reducing the formation of ice crystals in the extra and intracellular compartments, and

addition of cells to at least one substance of plant origin for the protection of the cells during the freezing and thawing phases.

The method according to the invention makes it possible to prepare the cells to better protect them during cryopreservation and makes it possible to obtain a larger number of living cells after cryopreservation. The method according to the invention also makes it possible to improve the viability different cell subpopulations and in particular those that are least represented.

Indeed, the use of several cryoprotectants reduces the cellular toxicity while maintaining the cryoprotective properties. The combination of high and low molecular weight cryoprotectants makes it possible to reduce ice crystal formations in the extra and intracellular compartments and thus protect the cells during the phase in which they are frozen.

Furthermore, the plant substance protecting the cells during the freezing and thawing phases provides mechanical protection for the cells against the mechanical stresses created by the formation of ice crystals in the extracellular medium and which can cause irreversible deformations on the cells.

In addition, the substance improving the oxygenation of the cells before and after freezing can preserve a large number of living cells during the phases before and after cryopreservation.

Thus, the process according to the invention makes it possible to provide protection before, between and after the freezing and thawing phases of the cells during cryopreservation of the cells and thus making it possible to improve the cryopreservation of cells.

Advantageously, the substance of vegetable origin may be a gel of plant origin, for example an agarose gel with a low gelling temperature, for example between 2 and 25 ° C., or alginate. At temperatures near 0 ° C, the formation of ice crystals in the extracellular medium causes mechanical stresses on the cells in suspension and therefore deformations that can be irreversible. The use of a gel of plant origin provides mechanical protection for the cells.

Advantageously, the cell oxygenation enhancing substance may be a saturated oxygen (0 ₂ ) transporter.

According to one embodiment of the composition according to the invention, the substance improving the oxygenation of the cells may comprise human or animal hemoglobin.

According to another version of the method of the invention, the substance improving the oxygenation of the cells may comprise a substitute for human or animal hemoglobin.

For example, such a substitute for hemoglobin may be selected from the family of fluorocarbons which are particularly effective oxygen carriers.

Advantageously, the combination of cryoprotectants may comprise:

a first cryoprotectant,

a second cryoprotectant having a lower toxicity than the toxicity of said first cryoprotectant,

a third cryoprotectant with oncotic property that protects the cells from edema;

the step of adding the cryoprotectant combination comprising the following sub-steps:

addition of the third cryoprotectant,

adding the second cryoprotectant after adding the third cryoprotectant, and - addition of the first cryoprotectant after addition of the second cryoprotectant.

Thus, the overall toxicity of the combination of cryoprotectants is lower than in the case where a single cryoprotectant is used.

According to an advantageous version of the invention, the step of adding the substance of plant origin can be carried out before or during the addition of the first cryoprotectant and after addition of the third cryoprotectant.

According to a particular embodiment, the combination of cryoprotectants may comprise the following cryoprotectants:

dimethylsulfoxide (DMSO), for example as the first cryoprotectant

- Trehalose, for example as a second cryoprotectant and

Polyethylene glycol (PEG) with a molecular mass of between 10 and 30 kDa, for example as a third cryoprotectant.

According to an exemplary embodiment, the concentration of the different cryoprotectants can be as follows:

the dimethylsulfoxide concentration is between 1 and 5% by volume,

the concentration of trehalose is between 0.05 and 1.5 moles, and

the concentration of polyethylene glycol is between 5 and 30 g / l.

The method according to the invention may further comprise a step of incubating the cells for a period of time. proportional to the final volume to cryopreserve. Such an incubation step allows the balance of the intracellular and extracellular concentration of the cryoprotectant (s) (intracellular type)

DMSO is a widely used cryoprotectant but exhibits significant cellular toxicity. This toxicity increases with the concentration of DMSO.

The addition of trehalose, which has lower cytotoxic effects than DMSO, makes it possible to use a lower concentration of DMSO, which is therefore less cytotoxic, while retaining a cryoprotective effect of the same nature. Thus, the combination of cryoprotectants has low toxicity.

In addition to its cryoprotectant property, PEG has oncotic potency in solution which protects the cells from edema.

According to an advantageous version of the invention, the addition step of the plant substance, which may preferably be a polysaccharide gel, may be carried out after the addition of the first cryoprotectant.

The substance of plant origin may advantageously be a substance whose gelling point is less than or equal to 12 ° C. Indeed, DMSO has a significant cellular toxicity. This toxicity is moderate at a temperature of less than or equal to 12 ° C. The polysaccharide gels have a variable gelation temperature generally greater than 20 ° C. It is therefore advantageous to use a polysaccharide gel whose gel point is less than 12 ° C., a temperature above which the toxicity of DMSO is significant (or greater). According to another aspect of the invention, there is provided a method of cryopreservation of cells, characterized in that it comprises a cryopreservation phase comprising the following steps:

treatment of the cells according to the treatment method according to the invention,

freezing said treated cells until cryogenization.

Advantageously, the freezing step may comprise:

a step of slow cooling to a temperature between -30 and -50 ° C, for example from 0.5 to 3 ° C per minute), and

a faster cooling step to a temperature of -130 ° C, for example 5 to 10 ° C per minute).

The cryopreserved cells thus obtained can then be transferred to a temperature-controlled cryogenic chamber.

The cryopreservation method according to the invention may further comprise a thawing phase of the cryopreserved cells, said thawing phase comprising:

a step of slow thawing to a temperature between -80 and -100 ° C, for example 5 to 10 ° C per minute, and

a faster rapid thawing step to a temperature of the order of 20 ° C, for example 10 to 20 ° C per minute. According to a particular embodiment of the cryopreservation method according to the invention, the rapid thawing step can be carried out in a water bath at a temperature between 36-42 ° C.

The cryopreservation method according to the invention may also comprise a step of washing the thawed cells with a cell washing solution.

After the cell wash phase, the method may include a step of adding a saturated oxygen carrier.

Other advantages and characteristics will appear on examining the detailed description of a non-limiting embodiment.

The example which will be described in the rest of the application relates to the treatment and cryopreservation of human lymphocyte cells.

Human lymphocyte cells are treated according to a treatment method for their cryopreservation. This method of treatment comprises the following steps:

addition of an oxygen carrier, for example a perfluorocarbon perfluorodecalin type, previously loaded with oxygen at a dose between 1 and 10% by volume at a temperature between 20 and 25 ° C and with slow stirring;

the addition of Poly Ethylene Glycol, for example, of molecular weight MW 20,000 between 10 and 20 g / L finally at a temperature between 20 and 25 ° C. and with slow stirring; - Gradual addition of trehalose to reach a final concentration between 0.1 and 0.5 M in 30 minutes at a temperature between 20 and 25 ° C and with slow stirring;

- Gradual addition of DMSO to a final concentration of between 1 and 5% by volume at a temperature between 8 and 12 ° C;

incubation between 8 and 12 ° C. for a duration proportional to the final volume of the product to be cryopreserved, for example 4 minutes for a 100 ml bag;

progressive addition of a gel, for example an agarose gel with a very low gelation temperature, at a concentration of between 0.2 and 0.8% in the final solution at a temperature between 8 and 12 ° C .;

- transfer to the system providing the programmed freezing previously cooled to + 4 ° C and start of the freezing procedure.

The different components are added to the cells as a liquid solution

This cryopreservation method comprises a step of freezing the cells achieving a controlled temperature descent to bring the treated cells to a temperature of the order of -130 ° C.

The freezing comprises a first phase of slow cooling between 0.5 and 3 ° C per minute to a temperature between -30 and -50 ° C and then a second phase of rapid cooling, between 5 to 10 ° C per minute to, at a temperature of the order of -130 ° C.

The cryopreserved cells are transferred to a temperature-controlled cryogenic chamber. The cryopreservation method also includes a defrosting step prior to reuse of cells. The thawing step is carried out in several phases:

a slow thawing phase up to a temperature of between -100 and -80 ° C., and

- A rapid thawing phase in a water bath at 38-40 ° C to a temperature close to 20 ° C.

After the rapid thawing phase, the cell cryopreservation method also comprises a step of gradually adding a cellular washing solution, such as a buffered solution containing glucose, for example based on Ringer's solution.

After the cell washing phase, the method comprises a step of adding the saturated oxygen carrier.

Of course, the invention is not limited to the examples which have just been described.

Claims

A method of treating cells for the cryopreservation of said cells, characterized in that it comprises the following steps:

adding cells to at least one saturated oxygen carrier prior to freezing and after thawing, said oxygen carrier comprising human or animal hemoglobin and / or a human or animal hemoglobin substitute, addition to cells a combination of high and low molecular weight cryoprotectants reducing the formation of ice crystals in the extra and intracellular compartments, and

adding at least one gel of plant origin to the cells for protection during the freezing and thawing phases, said gel of plant origin comprising agarose and / or alginate.

2. Method according to claim 1, characterized in that the substitute for hemoglobin is selected from the family of fluorocarbons.

3. Method according to any one of the preceding claims, characterized in that the combination of cryoprotectants comprises:

a first cryoprotectant,

a second cryoprotectant having a lower toxicity than the toxicity of said first cryoprotectant, a third cryoprotectant with oncotic property that protects the cells from edema.

the addition step of the cryoprotectant combination comprising the following sub-steps

addition of the third cryoprotectant,

adding the second cryoprotectant after adding the third cryoprotectant, and

addition of the first cryoprotectant after addition of the second cryoprotectant.

4. Method according to claim 3, characterized in that the step of adding the gel of plant origin is carried out before or during the addition of the first cryoprotectant and after addition of the third cryoprotectant.

5. Method according to any one of the preceding claims, characterized in that the combination of cryoprotectants comprises the following cryoprotectants:

dimethylsulfoxide (DMSO),

- Trehalose, and

- Polyethylene glycol (PEG) with a molecular mass of between 10 and 30 kDa.

6. Method according to claim 5, characterized in that:

the dimethylsulfoxide concentration is between 1 and 5% by volume,

the concentration of trehalose is between 0.05 and 2 moles, and

the concentration of polyethylene glycol is between 5 and 30 g / l.

7. Method according to any one of the preceding claims, characterized in that it comprises a step of incubating the cells for a duration proportional to the final cryopreserver volume.

8. Process for the cryopreservation of cells, characterized in that it comprises a cryopreservation phase comprising the following steps:

treating the cells according to the method according to any one of the preceding claims,

freezing said treated cells until cryogenization.

9. Process according to claim 8, characterized in that the freezing step comprises:

a step of slow cooling to a temperature between -30 and -50 ° C, (0.5-3 ° C / minute), and

a faster cooling step to a temperature of -130 ° C (5-10 ° C / minute).

10. Method according to any one of claims 8 or 9, characterized in that it further comprises a defrosting phase cryogenic cells, said defrosting step comprising:

a slow thawing step to a temperature between -80 and -100 ° C, and a quicker defrosting step to a temperature of about 20 ° C.

11. The method of claim 10, characterized in that it comprises a step of washing the thawed cells with a cell washing solution.